Clinical Research Directory
Browse clinical research sites, groups, and studies.
GKL-006Allo Injection in Patients With Advanced Solid Tumors
Sponsor: Beijing Gene Key Life Technology Co., Ltd
Summary
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.
Official title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006Allo Injection in Patients With Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2026-08-30
Completion Date
2029-01-31
Last Updated
2026-07-15
Healthy Volunteers
No
Conditions
Interventions
GKL-006Allo Injection
GKL-006Allo Injection is an allogeneic invariant natural killer T (iNKT) cell therapy. It will be administered according to the dose level, dosing schedule, and treatment stage specified in the protocol.
Locations (1)
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China